MetaCap

InflaRx N.V. (IFRX)

NASDAQ: IFRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.04-0.05 (-4.59%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IFRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$153.26M
EPS (TTM)
-$0.37
52-week range
0.798 – 2.95
Day range
1.03 – 1.12
Volume / Avg
472.11K / 868.66K
Beta
—

52-week range

$0.798$2.95

IFRX stock today

Shares of InflaRx N.V. (IFRX) finished lower on Nov 20 at $1.04, a drop of 4.59% or $0.05 per share, versus the S&P 500's 3.70% decline. Shares are 64.7% below their 52-week high of $2.95, set on May 7, 2026 and 30.3% above the 52-week low of $0.798, near the bottom of the past year's range. IFRX is up 3.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.9%.

InflaRx N.V. has posted a net loss over the last twelve months (EPS of -$0.37), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About InflaRx N.V.

Company profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Prof. Niels C. Riedemann M.D., Ph.D.
Headquarters
Jena
Employees
65
IPO year
2017
Website
inflarx.de

Analyst forecast

Forecast

Consensus (8 analysts)

none

Avg. price target

$8.28+696.15%

  • Strong buy 1
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.89High $13.34

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.02 vs $-0.07
Surprise
+71.43%

IFRX news

All IFRX news

InflaRx N.V. peers

Health Care sector
IFRX peer companies
CompanyPrice% ChgMarket capCompare
ORMPOramed Pharmaceuticals Inc.3.57-3.25%$155.24Mvs IFRX
ELDNEledon Pharmaceuticals Inc.1.78-6.32%$150.34Mvs IFRX
RNAAtrium Therapeutics Inc.6.92-0.86%$149.27Mvs IFRX
VRXAVeraxa Biotech AG1.04+0.97%$147.06Mvs IFRX
PRQRProQR Therapeutics N.V.1.04-0.95%$146.98Mvs IFRX
BBOTBridgeBio Oncology Therapeutics Inc.1.81-2.69%$145.25Mvs IFRX
EMISEmmis Acquisition Corp. Class A10.36+0.15%$163.36Mvs IFRX
ABEOAbeona Therapeutics Inc.2.42-1.22%$165.31Mvs IFRX

Indexes, lists and sector

InflaRx N.V. stock FAQ

What is InflaRx N.V.'s stock price today?

IFRX last traded at $1.04 as of Nov 20, 4:00 PM EST, down 4.59% on the day. Prices are delayed at least 15 minutes.

Who is InflaRx N.V.'s CEO?

Prof. Niels C. Riedemann M.D., Ph.D. is the chief executive officer of InflaRx N.V., which has about 65 employees.

What is the IFRX 52-week high?

The 52-week high for IFRX is $2.95 and the 52-week low is $0.798. The stock is currently 64.7% below its high.

Compare IFRX